In re Application of: PETERSEN et al.

Application No.:

10/651,829

Page 2 of 6

## **CLAIM LISTING**

Claim 1. (Withdrawn). A method for producing a cell that expresses a neural cell phenotype, the method comprising the steps of:

- (a) providing an hepatic oval cell; and
- (b) placing the hepatic oval cell under conditions that promote the differentiation of the hepatic oval cell into a cell that expresses a neural cell phenotype.
- Claim 2. (Withdrawn). The method of claim 1, wherein the neural cell phenotype comprises expression of marker selected from the group consisting of: NFM, nestin, MAP2, βIII tubulin, α-internexin, GFAP, S100, and CD11b.
- Claim 3. (Withdrawn). The method of claim 1, wherein step (b) comprises contacting the hepatic oval cell with an agent increases cAMP concentration in the hepatic oval cell.
- Claim 4. (Withdrawn). The method of claim 3, wherein the agent is an analogue of cAMP.
- Claim 5. (Withdrawn). The analogue of claim 4, wherein the analogue is dibutyryl cAMP.
- Claim 6. (Withdrawn). The method of claim 3, wherein the agent is an inhibitor of cAMP phosphodiesterase.
- Claim 7. (Withdrawn). The method of claim 6, wherein the agent is 3-isobutyl-1-methylxanthine.
- Claim 8. (Withdrawn). The method of claim 1, wherein step (b) comprises culturing the hepatic oval cell with a neurosphere.

In re Application of: PETERSEN et al.

Application No.:

10/651,829

Page 3 of 6

Claim 9. (Withdrawn). The method of claim 1, wherein step (b) comprises transplanting the hepatic oval into a central nervous system tissue in an animal.

Claim 10. (Withdrawn). The method of claim 9, wherein the central nervous system tissue is a brain.

Claim 11. (Currently Amended). A cell that expresses a neural cell phenotype, the cell being made according to the method of claim 1 wherein the cell is cultured in media comprising an agent which increases cAMP concentration in the cell.

Claim 12. (Currently Amended). The cell of claim 11, wherein the cell expresses are a marker: selected from the group consisting of: NFM, nestin, MAP2, βIII tubulin, α-internexin, GFAP, S100, and CD11b.

Claim 13. (Withdrawn). The cell of claim 11, wherein the marker is NFM.

Claim 14. (Withdrawn). The cell of claim 11, wherein the marker is nestin.

Claim 15. (Withdrawn). The cell of claim 11, wherein the marker is MAP2.

Claim 16. (Withdrawn). The cell of claim 11, wherein the marker is \( \beta \text{III} \) tubulin.

Claim 17. (Withdrawn). The cell of claim 11, wherein the marker is  $\alpha$ -internexin.

Claim 18. (Withdrawn). The cell of claim 11, wherein the marker is GFAP.

Claim 19. (Withdrawn). The cell of claim 11, wherein the marker is S100.

Claim 20. (Withdrawn). The cell of claim 11, wherein the marker is CD11b.

In re Application of: PETERSEN et al.

Application No.:

10/651,829

Page 4 of 6

Claim 21. (Withdrawn). A method of introducing a cell into a host animal subject, the method comprising the steps of:

- (a) providing the animal subject; and
- (b) introducing into the subject a cell made according to the method of claim 1.